IGF1 and acute myeloid leukemia: In AML samples, increased levels of IGF-1 and associated binding proteins (IGF-BP) were shown to correlate with prognosis, which leads to the assumption that these markers have the potential to serve as predictive tools for tracing residual disease load [147].